A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Clinical trial NCT05756153 · COMPLETED
Trial details
- NCT number
- NCT05756153
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-25
- Primary completion
- 2025-04-30
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.